Alterations in EGFR, as well as in other genes such as KRAS mutations or ALK translocations, are frequent in lung adenocarcinoma; all these changes have been involved in the activation of signaling pathways critical in lung tumorigenesis, such as MAPK and PI3K/AKT pathways [12–14]. This evidence concerns the gene ALK and lung adenocarcinoma.